Clinical trials: Cancer of Nasopharynx
Nasopharyngeal Carcinoma
NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
By this clinical trial, the investigators are trying to give an answer to such a question. Whether NPC patients staged N2-3M0 need adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation?
- Trial name
- NCT01694576
- Testing
- Adjuvant chemotherapy with paclitaxel and nedaplatin
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Nasopharyngeal Cancer
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT01074021
- Testing
- Nimotuzumab
- Where
- 24 sites in China
- Volunteers
- 480 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT03025958
- Testing
- Nimotuzumab, Radiation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is a head and neck tumor. Studies have shown that more than 70% of patients are diagnosed with locally advanced nasopharyngeal carcinoma at the time of initial diagnosis.
- Trial name
- NCT05508347
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Hypotension, ENT Disease
Influence of the "Hypotension Probability Index" on Intraoperative and Postoperative Hypotension in ENT- and OM-Surgery
The aim of the project is to investigate whether the use of the HPI can reduce the number and duration of intra- and postoperative hypotension in ventilated patients during and two hours after extensive surgery in the head and…
- Conditions
- Hypotension, ENT Disease, Acute Kidney Injury, Anesthesia
- Trial name
- NCT04151264
- Testing
- Hypotension probability index (HPI)
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- University of Giessen
Nasopharyngeal Carcinoma
Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is a prevalent disease in southeast of China. Radiation therapy with or without chemotherapy is a standard therapy for nasopharyngeal cancer.
- Trial name
- NCT01534585
- Testing
- Icotinib, intensity-modulated radiotherapy, Paclitaxel and Cisplatin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Taizhou Hospital
Oral Mucositis (Ulcerative) Due to Radiation, Nasopharyngeal Carcinoma (NPC)
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
This clinical trial aims to understand whether taurine can prevent and reduce severe radiation-induced oral mucositis in patients with nasopharyngeal carcinoma undergoing radiotherapy.
- Trial name
- NCT07567742
- Testing
- Taurine
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinom, Nasopharyngeal Carcinoma
The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC
A phase I/II clinical study of JS004 in subjects with head and neck cancer in China, to evaluate the safety, tolerability, PK, immunogenicity, antitumor activity and biomarkers of JS004, define the RP2D.
- Trial name
- NCT04929080
- Testing
- JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion, JS001 and JS004
- Where
- China
- Volunteers
- 149 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Nasopharyngeal Neoplasms, Radiodermatitis
Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
Radiation therapy remains the principal treatment for nasopharyngeal carcinoma (NPC). Although intensity modulated radiation therapy (IMRT) has been widely used in China nowadays, radiation dermatitis is still common.
- Trial name
- NCT02729324
- Testing
- Medical Radiation Protectants (FORRAD®), Trolamine (Biafine)
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Yun-fei Xia
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer
- Trial name
- NCT03144661
- Testing
- INCB062079
- Where
- 6 sites in United States, Belgium
- Volunteers
- 25 people
- Sponsor
- Incyte Corporation
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00003580
- Testing
- amifostine trihydrate, cisplatin, radiation therapy
- Where
- United States
- Sponsor
- University of Tennessee
Nasopharyngeal Carcinoma
The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma
The purpose of this study in to observe the effectiveness and safety of paclitaxel (albumin-bound type) combined with cisplatin, PD-1 inhibitor and IMRT in the treatment of locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT04769076
- Testing
- Paclitaxel（Albumin-bound）
- Volunteers
- 40 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nasopharyngeal Carcinoma, Quality of Life
Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC
This study is a multicenter, non-inferiority, open-label, randomized controlled Phase III clinical trial. It aims to compare the efficacy of modified delineation radiotherapy (experimental group) versus standard delineation…
- Conditions
- Nasopharyngeal Carcinoma, Quality of Life, Thyroid Diseases, Radiotherapy Side Effect
- Trial name
- PROTECT-NPC (NCT06752239)
- Testing
- Modified delineation, Standard delineation
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Nasopharyngeal Cancinoma (NPC)
LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
This study aims to evaluate the efficacy and toxicity of adding low-dose radiotherapy to chemoimmunotherapy as a first-line treatment for nasopharyngeal carcinoma patients with liver metastasis.
- Trial name
- Light (NCT06788002)
- Testing
- Low-dose radiotherapy combine with chemoimmunotherapy
- Where
- 8 sites in China
- Volunteers
- 26 people
- Sponsor
- Hunan Cancer Hospital
Nasopharyngeal Carcinoma
A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
This is a randomized, open, multicenter phase II/III trial to compare the efficacy and safety of QL1706 and carrilizumab combined with gemcitabine and cisplatin in first-line treatment of recurrent or metastatic nasopharyngeal…
- Trial name
- NCT05576272
- Testing
- QL1706, Carrelizumab, Gemcitabine
- Where
- China
- Volunteers
- 460 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Head and Neck Cancer
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00022217
- Testing
- carboplatin, cisplatin-e therapeutic implant, paclitaxel
- Where
- 4 sites in United States
- Sponsor
- Matrix Pharmaceutical
Locally Advanced Nasopharyngeal Carcinoma
Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
The clinical efficacy of nivolumab for locally advanced nasopharyngeal carcinoma patients with residual disease after standard chemoradiotherapy is not known.
- Trial name
- NCT04910347
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 57 people
- Sponsor
- Yonsei University
Carcinoma of Unknown Primary, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
This trial uses blood tests and questionnaires to study how well participants with head and neck cancer that has spread to other places in the body adhere to swallowing exercises to prevent future disease.
- Conditions
- Carcinoma of Unknown Primary, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT03010150
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- United States
- Volunteers
- 471 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma (NPC), Screening
Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
This study is a prospective, self-controlled, multicenter clinical trial. All participants will be tested for Epstein-Barr virus (EBV) associated biomarkers, including the two-antibody method (VCA-IgA and EBNA1-IgA), BNLF2b total…
- Conditions
- Nasopharyngeal Carcinoma (NPC), Screening, Epstein Barr Virus
- Trial name
- NCT06870435
- Testing
- Blood, nasopharyngeal swab and saliva, EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA, Novel screening biomarkers
- Where
- China
- Volunteers
- 68,649 people, healthy volunteers welcome
- Sponsor
- Ming-Yuan Chen
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.